The Latest Cardiac and Vascular News
ANN ARBOR, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the presentation of results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. Results were also simultaneously published […]
ANN ARBOR, Mich., Aug. 26, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the presentation of results from two oral presentations at the Late-Breaking Science Session entitled, “Clinical trial updates on prevention and lipid lowering” at the European Society […]
ANN ARBOR, Mich., Aug. 01, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today reported financial results for the second quarter ended June 30, 2023, and provided a business update. “We posted strong results in the second quarter of 2023, reflecting […]
– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that the application was filed for […]
Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists’ (CTT) Major Vascular Event endpoint is comparable to the normalized risk reduction with statins observed in the CTT meta-analyses ANN ARBOR, Mich., June 15, 2023 (GLOBE NEWSWIRE) — […]
– Submitted four efficacy supplements seeking inclusion of CV risk reduction and expansion of LDL-C lowering – – Anticipated approvals in U.S. in the first half of 2024 – ANN ARBOR, Mich., June 01, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced […]
– U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q – – Strengthened Capital Position with $56 Million in Financing – – Global […]
– Gibson Dunn Files Amended Complaint with Powerful New Evidence – ANN ARBOR, Mich., May 04, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) announced today that it has retained Gibson Dunn to vindicate its contractual rights against Daiichi Sankyo Europe […]
– Performance-Based Agreement Provides for Currax’s 72 Sales Representatives to Detail Esperion’s Products – – Reinforces Esperion’s Focus on Driving Persistent Growth By More Than Doubling Sales Team – ANN ARBOR, Mich., April 19, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced an […]
ANN ARBOR, Mich., March 20, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 33,170,747 […]
